Archives
-
Caspase-3 Colorimetric Assay: Evidence Scope
2026-10-14
A source-limited overview of the K2008 Caspase-3 Colorimetric Assay Kit, its DEVD-pNA measurement principle, and the boundaries between a biochemical activity signal and evidence of apoptosis.
-
TMEM16F, Kupffer Cells and Liver Inflammation
2026-10-14
A 2024 Advanced Science study examined whether TMEM16F protects against Listeria monocytogenes primarily through T cells, B cells, or liver Kupffer cells. Using cell-type-specific mouse models and cellular, tissue, inflammatory, and metabolic readouts, the authors reported that Kupffer-cell TMEM16F was central to limiting membrane injury and liver pathology. The supplied study does not report use of Ac-YVAD-CMK, so it cannot establish that caspase-1 inhibition explains the observed phenotype.
-
Q-VD-OPh: What the Evidence Really Shows
2026-10-13
Q-VD-OPh is widely described as an irreversible pan-caspase inhibitor, but its value in apoptosis research depends on how broadly caspase activity is interpreted and how well pharmacological effects are separated from other cell-death pathways. A 2022 Cell Reports study used caspase inhibition within a model of post-near-death tumor-cell states, linking survival from impending cell death with prometastatic behavior. The findings are mechanistically important but remain bounded by model choice, pharmacological specificity and the absence of clinical evidence.
-
RHEB Neddylation: Evidence and Open Gaps
2026-10-13
A source-grounded assessment of the reported UBE2F–SAG–RHEB–mTORC1 relationship, emphasizing what the 2025 study establishes, what remains correlative, and why the X-press Tag Peptide product description should not be treated as evidence for the cancer mechanism.
-
Cisapride and Deep-Learning Cardiotoxicity Screens
2026-10-12
The reported study supports iPSC-derived cardiomyocytes combined with high-content imaging and deep learning as an exploratory approach to detect cellular patterns associated with cardiotoxicity. It does not, from the supplied evidence, establish that Cisapride or R 51619 was included in the screened library, nor does it replace mechanistic, electrophysiological, translational, or clinical evaluation.
-
HIV-1 Nuclear Pore Remodeling in Resting T Cells
2026-10-10
Mesner et al. identify nuclear import at the nuclear pore complex as a major barrier to HIV-1 infection of resting CD4+ T cells and show how cell–cell spread overcomes it. The study links virological-synapse contact to CD4–LCK signalling, CDK1 activation, nucleoporin phosphorylation and enhanced viral nuclear import, offering a mechanistic explanation for infection of resting T cells in vivo.
-
RSL3 and GPX4 Inhibition in Ferroptosis Research
2026-10-09
RSL3 is a widely used glutathione peroxidase 4 inhibitor for investigating ferroptosis, redox vulnerability, and cancer-cell dependence on lipid peroxide control. This overview compares mechanistic evidence, oncogenic RAS associations, preclinical tumor findings, and important limitations, including compound-specific confounding and the absence of clinical validation.
-
Cisplatin and Ferroptosis: Five Key Questions
2026-10-09
A source-grounded overview of Cisplatin and CDDP research, explaining DNA damage principles, the evidence for Buzhong Yiqi Decoction in a cisplatin-resistant lung cancer cell model, and the study’s limitations and applicability boundaries.
-
ATF5 Peptide Downregulates CYP2B6 in Glioblastoma
2026-10-08
A 2025 study identifies ATF5 as a regulator of CYP2B6 in glioblastoma cells and shows that a TAT-fused dominant-negative ATF5 peptide lowers CYP2B6 protein in LN229 and GBM5 models. The findings connect transcription-factor biology with pharmacogenomics, while remaining preliminary because the study did not establish altered drug metabolism, clinical dosing effects, or in vivo efficacy.
-
Psoralen and Isopsoralen Activate ERK1/2 in Cholestasis
2026-10-08
A 2024 Chemical Research in Toxicology study used zebrafish larvae to connect the estrogen-like activity of psoralen and isopsoralen with cholestatic liver injury, altered bile-acid regulation, and increased ERK1/2 phosphorylation. Pharmacological rescue supports ERK1/2 as a mechanistically relevant node, while the model remains insufficient to establish human clinical risk or therapeutic efficacy.
-
Z-YVAD-FMK in Ferroptosis and Caspase-1 Research
2026-10-07
Z-YVAD-FMK is commonly presented as a caspase-1 inhibitor for studying inflammasome signaling and pyroptosis. Its relevance to ferroptosis research is indirect: the supplied AML study identifies dihomo-γ-linolenic acid and ACSL4-mediated lipid remodeling as drivers of ferroptotic leukemia-cell death, but it does not establish a role for caspase-1 or report use of Z-YVAD-FMK. This overview compares the pathways, explains what the published findings support, and defines the evidence and applicability limits without treating supplier claims as independent validation.
-
Z-YVAD-FMK in Caspase-1 and Pyroptosis Research
2026-10-07
A source-grounded overview of Z-YVAD-FMK as a research tool for studying caspase-1, pyroptosis, and inflammatory cell death, with emphasis on the HOXC8–CASP1 axis in non-small cell lung cancer and the limits of translating YVAD-based pharmacology to this specific compound.
-
Enzymatic Fatty Amine Synthesis from Trilaurin
2026-10-06
The reference study presents a one-pot enzyme cascade that converts renewable triglycerides and oils directly into medium- and long-chain primary fatty amines. Using Trilaurin as a representative substrate, the authors report analytical yields up to 97% and a 73% isolated yield for laurylamine, while also defining the proof-of-concept limits of the approach.
-
Cycloheximide in Protein Turnover Research
2026-10-06
Cycloheximide is a translational elongation inhibitor used conceptually to study protein synthesis, protein turnover, apoptosis, and cellular stress. This overview distinguishes supplier-reported properties from findings in a peer-reviewed triple-negative breast cancer study, explaining how translation suppression may help frame questions about protein stability without treating it as direct evidence for a therapeutic mechanism. It also compares evidence strength, highlights cytotoxicity and model-specific limitations, and defines boundaries for interpreting findings across cell, animal, and clinical contexts.
-
α-Amanitin: Mechanism, Research Uses, and Evidence
2026-10-05
A source-grounded overview of α-amanitin as an RNA polymerase II research probe, its conceptual applications in transcription and development studies, and emerging evidence linking STT3B and N-glycan biosynthesis to amatoxin toxicity.